drugset
drugset / Trial / NCT01430078

A Study to Assess the Bioavailability of ASP015K

NCT01430078 ↗

Phase 1 Completed 12 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-label

Summary

The objective of the study is to assess the bioavailability of ASP015K within the gastrointestinal tract.

Timeline

Start
2010-09
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule — Oral

Indications

No indication recorded.